Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of ixabepilone with or without cetuximab in first-line triple-negative advanced or metastatic breast cancer
2007-005209-23Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Ixabepilone monotherapy with Ixabepilone + cetuximab (2 arms). Primary endpoint: Objective response. Started Feb 2008; status: completed.
02
Drugs
ixabepilonecetuximab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2007-005209-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005209-23.